Breast Cancer

ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The AI program also correctly identified 90% of true positive cases, according to new data presented at the Society for Breast Imaging's annual symposium.

New data to be presented at ECO 2025 shows new-onset T2D is linked to increased risk of liver, pancreatic, and bowel cancers, but not endometrial or post-menopausal breast cancer.

While smoking in the US continues to decline, the American Cancer Society reports mixed progress in major cancer risk factors, prevention, and screening.

ACP 2025: Dr Kalager shares strategies for addressing patient beliefs, presenting risk data, and promoting shared decision-making in primary care settings.

Myths and fears about cancer screening may be keeping some of your patients from important tests. Always ask about misconceptions, and then offer the facts.

Your daily dose of the clinical news you may have missed.

Cervical cancer screening rates remained below prepandemic levels, while rates for breast and colorectal cancers rebounded from pandemic declines.